All In Biotech

Drug Trial Radar · NCT06045754

A Study of Vedolizumab Intravenous (IV) and Adalimumab or Vedolizumab and Ustekinumab in Adults With Crohn's Disease

An Open-Label, Phase 4 Study to Evaluate the Efficacy and Safety of Dual Targeted Therapy With Vedolizumab Intravenous (IV) and Adalimumab Subcutaneous (SC) or Vedolizumab IV and Ustekinumab IV/SC in Moderate to Severe Crohn's Disease (CD)

Last checked: Nov 20, 2026Latest source record: Oct 23, 2026 (this record)Source: ClinicalTrials.govMethods & limitations

Active, not recruiting

Status

Active, not recruiting

Enrollment

50

Planned (sponsor's estimate)

Start

Apr 18, 2024

Primary completion

Jun 28, 2027

Study completion Jun 28, 2027

Sponsor

Lead sponsor
TakedaTakeda (TAK)
Sponsor type
Industry
First posted
Sep 21, 2023

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 4
Allocation
Non randomized
Model
Parallel
Masking
None
Primary purpose
Treatment
FDA-regulated drug
Yes
Who can join
All sexes, from 18 years, up to 70 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

The main aim of this study is to learn about the effect of treatment with vedolizumab IV (vedolizumab) together with adalimumab or vedolizumab (VDZ) together with ustekinumab (UST) in adults with moderate to severe Crohn's Disease, and the effect of treatment with vedolizumab alone, after the dual targeted treatment. The study is conducted in two parts. In Part A, participants will receive the dual targeted treatment (vedolizumab together with either adalimumab or ustekinumab). In part B, participants will receive vedolizumab only. Part B will include participants who responded to the treatment in Part A. Each participant will be followed up for at least 26 weeks after the last dose of treatment.

Conditions

  • Crohn's Disease

Interventions

  • VedolizumabDrug

    Vedolizumab intravenous infusion.

  • AdalimumabDrug

    Adalimumab subcutaneous injection.

  • UstekinumabDrug

    Ustekinumab intravenous infusion.

  • UstekinumabDrug

    Ustekinumab subcutaneous injection.

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Part A: Percentage of Participants With an Endoscopic Response Based on the Simple Endoscopic Score for (SES-CD) at Week 26Time frame: At Week 26
  2. Part B: Percentage of Participants With an Endoscopic Response Based on the SES-CD at Week 52Time frame: At Week 52

Locations

48 sites in 2 countries. Site status is shown where the registry gives one.

  • Digestive Health Specialsits

    Dothan, Alabama

  • GI Alliance Sun City

    Sun City, Arizona

  • University of California San Diego Health (UCSD)

    La Jolla, California

  • Cedars-Sinai Medical Center

    Los Angeles, California

  • Hoag Hospital Newport Beach

    Newport Beach, California

  • Medical Research Center of Connecticut, LLC

    Hamden, Connecticut

  • Clinical Research of Osceola

    Kissimmee, Florida

  • Endoscopic Research Inc

    Orlando, Florida

  • Alliance Clinical Research of Tampa, LLC

    Tampa, Florida

  • Gastroenterology Consultants, P.C.

    Roswell, Georgia

  • University of Chicago Medicine

    Chicago, Illinois

  • University of Kansas Medical Center

    Kansas City, Kansas

  • Cotton ONeil Clinical Research Center

    Topeka, Kansas

  • University of Louisville

    Louisville, Kentucky

  • GI Alliance

    Metairie, Louisiana

  • Tulane University

    New Orleans, Louisiana

  • Huron Gastroenterology Associates, P.C.

    Ypsilanti, Michigan

  • Mid-America Gastro-Intestinal Consultants

    Kansas City, Missouri

  • BVL Clinical Research

    Liberty, Missouri

  • Washington University School of Medicine

    St Louis, Missouri

  • NYU Langone Health

    New York, New York

  • University of Cincinnati

    Cincinnati, Ohio

  • Ohio Gastroenterology group, Inc.

    Columbus, Ohio

  • Great Lakes Gastroenterology Research, LLC

    Mentor, Ohio

  • Gastro Intestinal Research Institute of Northern Ohio, LLC.

    Westlake, Ohio

  • Digestive Disease Specialists, Inc.

    Oklahoma City, Oklahoma

  • Allegheny Health Network

    Wexford, Pennsylvania

  • University Gastroenterology

    Providence, Rhode Island

  • Sanford Health Research

    Rapid City, South Dakota

  • Texas Digestive Disease Consultants Cedar Park

    Cedar Park, Texas

  • GI Alliance - Digestive Health Associates of Texas

    Dallas, Texas

  • The University of Texas Health Science Center at Houston

    Houston, Texas

  • Texas Digestive Disease Consultants Lubbock

    Lubbock, Texas

  • GI Alliance - Mansfield

    Mansfield, Texas

  • Gastroenterology Research of San Antonio, LLC

    San Antonio, Texas

  • Southern Star Research Institute, LLC.

    San Antonio, Texas

  • Texas Digestive Disease Consultants (TDDC), Southlake

    Southlake, Texas

  • Tyler Research Institute, LLC

    Tyler, Texas

  • GI Alliance - Webster

    Webster, Texas

  • University of Utah Health

    Salt Lake City, Utah

Showing 40 of 48 sites, US sites first. The full list is on the registry record.

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.